Local NAID (Benzydamin)
PreclinicalSmall molecule
Local NAID (Benzydamin) is one of 12 small molecule programs targeting Tonsillitis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Tonsillitis
#DrugCompanyPhaseTrials
1Zofran
NovartisApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Oruvail
WWyeth-Lederle Vaccines
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Tylenol
KKenvue Brands
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Decadron
AAspen Global Incorporated
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tonsillitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Local NAID (Benzydamin). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details